Transcatheter aortic valve replacement, first implant to FDA approval (2002-2011)
Alain Cribier implanted the first transcatheter aortic valve in 2002 in a patient too sick for surgery. Edwards then ran high-risk-only trials of its Sapien valve, and the US Food and Drug Administration approved it in 2011 for patients surgeons had turned down.
Approval was limited to inoperable and high-risk patients, with heart teams deciding who qualified.
As data accumulated, the procedure expanded to lower-risk patients and became routine in many hospitals, while the earlier high-risk indication remained the foundation of the evidence base.
TARGET follows the same sequence: a single-arm study in patients who cannot have surgery, followed by a regulatory filing. Whether Cardiovalve's indication widens will depend on post-approval data, just as it did for aortic valves.
